Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:40:59 EDT Fri 03 May 2024
Enter Symbol
or Name
USA
CA



Q:CRVS - CORVUS PHARMACEUTICALS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CRVS - Q1.02.00·2.211.11.92+0.1911.0380.16529391.81  2.08  1.754.19  1.0519:57:21May 0215 min RT 2¢

Recent Trades - Last 10 of 939
Time ETExPriceChangeVolume
19:57:21Q2.050.326
19:55:09Q2.050.32870
19:52:04Q2.050.321
18:47:22Q2.020.2925
18:43:41Q2.020.2910
17:27:40Q2.00090.27092,382
17:26:29Q2.050.32400
17:01:03Q2.05010.3201477
16:57:40Q2.05030.32031,100
16:57:03Q2.05040.32041,100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-02 16:02U:CRVSNews ReleaseCorvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024
2024-05-02 08:30U:CRVSNews ReleaseCorvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering
2024-04-09 16:01U:CRVSNews ReleaseCorvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
2024-03-19 16:02U:CRVSNews ReleaseCorvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
2024-03-13 16:02U:CRVSNews ReleaseCorvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024
2024-02-12 08:30U:CRVSNews ReleaseCorvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases
2024-02-08 16:05U:CRVSNews ReleaseCorvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma
2024-02-06 16:05U:CRVSNews ReleaseCorvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer
2024-01-23 17:00U:CRVSNews ReleaseCorvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell
2023-12-09 12:00U:CRVSNews ReleaseCorvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial
2023-11-07 16:01U:CRVSNews ReleaseCorvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 ‚  Financial Results
2023-11-02 09:15U:CRVSNews ReleaseCorvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition
2023-11-01 19:32U:CRVSNews ReleaseCorvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases
2023-10-31 16:02U:CRVSNews ReleaseCorvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023
2023-09-06 16:05U:CRVSNews ReleaseCorvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA
2023-08-08 16:01U:CRVSNews ReleaseCorvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results
2023-08-01 08:30U:CRVSNews ReleaseCorvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023
2023-07-06 12:59U:CRVSNews ReleaseCorvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818)
2023-06-29 07:00U:CRVSNews ReleaseCorvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR ‚  Precision Cancer Medicine International Conference
2023-06-15 07:00U:CRVSNews ReleaseCorvus Pharmaceuticals Presents New CPI-818 Interim Data at the International Conference on Malignant Lymphoma